Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT03493165

Enrollment

Unknown

Registered

2018-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Sarcoma

Single patient treatment with everolimus.

DRUGEverolimus

mTOR inhibitor

Sex/Gender

FEMALE

Age

18 Years to No maximum

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026